5 Drugs That Could Make Celgene the Best Biotech Stock of the Next Decade
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more.
Celgene's past success stemmed primarily from four drugs: Revlimid, Pomalyst, Otezla, and Abraxane. These drugs should continue to generate growth for the biotech in the future, with Revlimid on track to become the top-selling cancer drug in the world. However, the most important drugs in determining whether Celgene remains the best big biotech stock in the next decade are still in the pipeline. Here are the five drugs that will be most critical to Celgene's future success.
Image source: Getty Images.
Source: Fool.com